Excitatory amino acid (EAA) receptor-mediated events have recently been implicated in dopaminergic mechanisms of neurotoxicity. 2,4,5-Trihydroxyphenylalanine (6-hydroxy-DOPA, TOPA), the ortho-hydroxylated derivative of the dopamine precursor 2,4-dihydroxyphenylalanine (L-DOPA), has recently been reported to have neurotoxic properties which are blocked by CNQX, a specific antagonist of the AMPA class of non-Nmethyl-o-aspartate (non-NMDA) EAA receptors. We report here that 6-hydroxy-DOPA is a selective displacer of Olney et al. [10] recently reported that L-DOPA and its ortho-hydroxylated derivative 6-hydroxy-DOPA produced neurotoxic damage of the chick retina in a manner similar to that induced by the EAA agonists kainate and quisqualate. The non-NMDA receptor antagonist 6-nitro-7-cyano-quinoxaline-2,3-dione (CNQX) blocked neurotoxic effects of all the tested compounds, but the NMDA receptor antagonist MK-801 did not. In addition, 6-hydroxy-DOPA produced depolarizations of cultured rat hippocampal neurons which were blocked by CNQX but not by the NMDA receptor antagonist 2-amino-5-phosphonovalerate (APV) [1, 10, 14] . These results clearly indicated a potential interaction of 6-hydroxy-DOPA and AMPA receptors. The present experiments were directed towards this question.
Abnormal activation of excitatory amino acid (EAA) receptors has been implicated in the pathophysiology of various types of neurotoxic events including epilepsy [5] , neuronal damage resulting from hypoxia-ischemia [15] , olivopontocerebellar atrophy [13] , and Alzheimer's disease [9, 11] . Huntington's disease and Parkinson's disease are neurodegenerative diseases in which dopaminergic systems or their targets are preferentially affected. EAA receptor-mediated mechanisms have recently been implicated in the pathophysiology of both Huntington's disease [4] and Parkinson's disease [8, 17] . While the regional specificity of the neuropathologic changes seen in Huntington's and Parkinson's diseases is as yet unexplained, recent observations emphasize the importance of interactions between dopaminergic and EAA systems. MK-801, a specific antagonist of the N-methyl-D-aspartate (NMDA) subtype of EAA receptor, blocks methamphetamine-induced nigrostriatal toxicity [16] . In addition, several NMDA antagonists have been shown to block the neurotoxic effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the substantia nigra [17] . Olney et al. [10] recently reported that L-DOPA and its ortho-hydroxylated derivative 6-hydroxy-DOPA produced neurotoxic damage of the chick retina in a manner similar to that induced by the EAA agonists kainate and quisqualate. The non-NMDA receptor antagonist 6-nitro-7-cyano-quinoxaline-2,3-dione (CNQX) blocked neurotoxic effects of all the tested compounds, but the NMDA receptor antagonist MK-801 did not. In addition, 6-hydroxy-DOPA produced depolarizations of cultured rat hippocampal neurons which were blocked by CNQX but not by the NMDA receptor antagonist 2-amino-5-phosphonovalerate (APV) [1, 10, 14] . These results clearly indicated a potential interaction of 6-hydroxy-DOPA and AMPA receptors. The present experiments were directed towards this question.
Autoradiographic binding assays were performed according to previously published methods (Table I) 6-Hydroxy-DOPA has been shown to be a potent excitant of frog spinal neurons and a potent convulsant when injected intraventricularly in rats [2]. Olney et al. [10] reported that the dopamine precursor L-DOPA and its ortho-hydroxylated analogue 6-hydroxy-DOPA produced neurotoxic damage of the chick retina in a fashion reminiscent of EAA-induced neurotoxicity. While 6-hydroxy-DOPA is not normally found in mammalian brain, it can be generated from L-DOPA via the action of tyrosinase [7] . It is also possible that other pathways for the abnormal hydroxylation of L-DOPA could produce 6-hydroxy-DOPA. For example, manganese ions can catalyze the formation of 6-hydroxydopamine from dopamine. Although 6-hydroxy-DOPA can be converted to the dopamine neurotoxin 6-hydroxydopamine, injections of 6-hydroxy-DOPA, which permeates the blood-brain barrier, do not lead to depletions of striatal dopamine [6] . In the present study, 6-hydroxydopamine was not an effective displacer of EAA receptor binding.
Rosenberg et al. [14] recently demonstrated that 6-hydroxy-DOPA oxidizes in solutions of physiologic pH to form a compound which is a neurotoxin and a non-NMDA receptor agonist. They concluded that the active compound was likely to be an oxidation product of 6-hydroxy-DOPA rather than 6-hydroxy-DOPA itself. Although in the present study 6-hydroxy-DOPA was dissolved in solutions containing 1 mM ascorbate and the [3H]AMPA binding assay was performed at 4°C, we cannot exclude the possibility that oxidation occurred. Some degree of oxidation of 6-hydroxy-DOPA surely occurred, as evidenced by the change of solution color 57 from clear to reddish orange. Displacement of [aH]AMPA binding in our study may have then been due to the presence of an oxidized metabolite of 6-hydroxy-DOPA, rather than 6-hydroxy-DOPA itself. Since 6-hydroxy-DOPA oxidizes rapidly at physiologic pH, the present results are relevant in that a similar oxidation reaction is likely to occur in neural tissues.
Recent studies using chick retina preparations have demonstrated that 6-hydroxy-DOPA has neurotoxic properties [10, 14] . Electrophysiological responses and neurotoxic damage produced by 6-hydroxy-DOPA were blocked by the specific non-NMDA receptor EAA antagonist CNQX and not by the NMDA receptor antagonist APV, suggesting a specific involvement of non-NMDA EAA receptors [1, 10] . The present study confirms that 6-hydroxy-DOPA or a rapidly produced metabolite thereof selectively interacts with AMPA receptors and, to a lesser extent, kainate receptors. Both of these receptor types have been implicated in neurotoxic phenomena [3, 18] . Given that 6-hydroxy-DOPA can be produced by human melanocyte tyrosinase [7] , the possibility is raised that 6-hydroxy-DOPA or another abnormal metabolite of the catecholaminergic synthetic pathway could act as an endogenous neurotoxin. If such a neurotoxin were selectively generated only by catecholaminergic neurons, these same neurons or their target neurons would be selectively vulnerable to EAA receptor-mediated degeneration. Taken together, these observations provide a plausible mechanism for the regional specificity of neuronal death in both Huntington's disease and Parkinson's disease.
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